Eltroxin

Overdose

Symptoms

In most cases there will be no features. Signs of an overdose may include: fever, chest pain (angina), racing or irregular heartbeat, muscle cramps, headache, restlessness, flushing, sweating, diarrhoea, tremor, insomnia and hyperpyrexia. These signs can take up to 5 days to appear. Atrial fibrillation may develop. Convulsions occurred in one child. There may be increased toxicity in those with pre-existing heart disease.

Management:

Give oral activated charcoal if more than 10mg has been ingested by an adult or more than 5mg by a child, within 1 hour. If more than 10mg has been ingested by an adult or more than 5mg by a child, take blood 6-12 hours after ingestion for measurement of the free thyroxine concentration. The analysis does not need to be done urgently but can wait until the first working day after the incident. Patients with normal free thyroxine concentrations do not require follow up. Those with high concentrations should have outpatient review 3-6 days after ingestion to detect delayed onset hyperthyroidism. Features of clinical hyperthyroidism should be controlled with beta-blockers, e.g. propranolol.

Shelf life

36 months for polypropylene containers.

24 months for blister packs.

Eltroxin price

Average cost of Eltroxin 0.100 mg per unit in online pharmacies is from 0.33$ to 0.46$, per pack from 33$ to 46$.

Incompatibilities

None known.

List of excipients

Sodium Citrate BP

Lactose BP

Maize starch BP

Powdered acacia BP

Magnesium Stearate BP

Preclinical safety data

No further data of relevance.

Pharmacotherapeutic group

Thyroid hormones

Pharmacodynamic properties

Pharmacotherapeutic group: Thyroid hormones

ATC Code: H03AA01

Eltroxin is a tablet containing the hydrated form of Levothyroxine sodium which is used for the treatment of hypothyroidism. The Thyroid gland is dependant upon 2 active principles for it's main hormone activity. These are Levothyroxine (Tetraiodothyronine) and Tri-iodothyronine (see Goodman and Gilman, 1985). These closely related iodine containing amino acids are incorporated into the glycoprotein thyroglobulin. The chief action of these hormones is to increase the rate of cell metabolism. Levothyroxine is deiodinated in peripheral tissues to form Tri-iodothyronine which is thought to be active tissue form of thyroid hormone. Tri-iodothyronine is certainly more rapid acting and has shorter duration of action than Levothyroxine.

Pharmacokinetic properties

Levothyroxine sodium is incompletely and variably absorbed from the gastrointestinal tract. It is almost completely bound to plasma proteins and has a half-life in the circulation of about a week in healthy subjects, but longer during pregnancy in patients with myxoedema. A large portion of the Levothyroxine leaving the circulation is taken up by the liver. Part of a dose of Levothyroxine is metabolised to triiodothyronine. Levothyroxine is excreted in the urine as free drug, deiodinated metabolites and conjugates. Some Levothyroxine is excreted in the faeces. There is limited placental transfer of Levothyroxine.

Date of revision of the text

24/05/2018

Marketing authorisation holder

Mercury Pharma Group Ltd

Capital House, 85 King William Street,

London EC4N 7BL, UK

Special precautions for storage

Do not store above 25°C. Store in the original package in order to protect from light and moisture.

Nature and contents of container

Polypropylene container with tamper-evident low density polyethylene lid, containing 28, 56, 112, 100 or 1000 Eltroxin 100mcg tablets.

Blister packaging PVC/PVDC film (heat treated foil/heat seal lacquer) containing 28, 56 and 112 Eltroxin 100mcg tablets.

Not all pack sizes may be marketed.

Marketing authorisation number(s)

PL 10972/0032

Special precautions for disposal and other handling

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Date of first authorisation/renewal of the authorisation

28/04/2010